Sizing a Risk-Based Annual Sampling Plan for Medical Devices in the EU

Distributors and importers of medical devices in the European Union are integral to ensuring the safety and performance of products placed on the market. A robust, risk-based annual sampling plan is a cornerstone of their quality management system, enabling them to fulfil their responsibilities under the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR).

#The Role of Sampling in Distributor and Importer Obligations

Distributors and importers are not merely logistical handlers; they bear specific regulatory responsibilities. Central among these is the verification of device conformity. This involves checking that devices bear the CE mark, that the EU declaration of conformity has been drawn up, and that a UDI is assigned, where applicable. Article 14(2) MDR and Article 12(2) IVDR mandate these checks for distributors, while Article 13(2) MDR and Article 11(2) IVDR apply to importers.

Sampling is a practical method to conduct these checks efficiently and effectively. It allows for a systematic assessment of a representative portion of the devices being handled, particularly for large volumes or frequent consignments.

#Legal Basis for Sampling

The MDR and IVDR implicitly require a systematic approach to verifying device conformity and identifying non-conforming devices. While the regulations do not explicitly define "sampling plan," the requirements for market surveillance, incident reporting, and cooperation with authorities necessitate a structured approach to quality control. The distributor's obligation under Article 14(2)(b) MDR and Article 12(2)(b) IVDR to "check that the device bears the CE marking and that an EU declaration of conformity has been drawn up" can only be practically achieved through a documented process, which often includes sampling.

Similarly, importers are required by Article 13(2)(b) MDR and Article 11(2)(b) IVDR to verify that the manufacturer has drawn up the EU declaration of conformity and that the device bears the CE marking.

#Key Elements of a Risk-Based Sampling Plan

A risk-based sampling plan must consider several factors to ensure its effectiveness and compliance. The level of scrutiny applied should always be proportionate to the risk class of the device and other relevant factors.

#Device Risk Classification

This is the primary determinant of sampling intensity. Devices with higher risk classes (e.g., Class III under MDR, Class D under IVDR) necessitate more frequent and rigorous sampling than lower-risk devices (e.g., Class I under MDR, Class A under IVDR). The classification rules are detailed in Annex VIII of the MDR and Annex VIII of the IVDR.

#Device Type and Characteristics

The nature of the device, its complexity, intended use, and critical components influence the sampling approach. For example, sterile devices or those with active components may require specific types of checks during sampling.

#Supplier Performance History

A consistent history of conformity from a particular manufacturer or supplier may allow for reduced sampling frequency over time, provided this is justified by robust data. Conversely, a history of non-conformities warrants increased sampling.

#Volume and Frequency of Shipments

High-volume or frequent shipments may necessitate statistical sampling methods to ensure a representative sample without impeding supply chains unnecessarily. Less frequent, smaller shipments might allow for a higher percentage of inspection.

#Criticality of Checks

Some checks are more critical than others. For instance, verifying the presence of a CE mark is fundamental, whereas checking specific batch numbers might be part of routine record-keeping. The sampling plan must prioritise critical aspects.

#Developing the Sampling Methodology

The methodology for sampling should be clearly defined within the quality management system. This includes:

• Sampling Size: How many units from a batch or consignment will be inspected?
• Sampling Frequency: How often will sampling occur (e.g., per batch, per shipment, annually)?
• Sampling Points: Where in the process will sampling occur (e.g., upon goods receipt, during storage)? For more details, refer to Incoming Goods Inspection for Medical Devices: A Repeatable Verification Process.
• Inspection Criteria: What specific aspects will be checked during the sampling process?

Below is an illustrative table demonstrating how risk class might influence sampling parameters. These are examples; actual values must be determined based on a comprehensive risk assessment within the distributor's or importer's specific context.

It is essential to document the rationale for the chosen sampling parameters. For a deeper understanding of defining and documenting sampling methods, consider reviewing How to define and document a sampling method for medical devices under MDR.

#Common Mistakes in Practice

• No documented rationale: Sampling plans are implemented without clear justification for chosen frequencies or sample sizes.
• Static approach: The sampling plan is not reviewed or updated based on device performance, supplier history, or regulatory changes.
• Insufficient scope: Checks are limited to only superficial visual inspections, neglecting critical documentation verification or labelling accuracy.
• Lack of corrective action: Non-conformities identified during sampling do not trigger appropriate investigations or corrective and preventive actions (CAPAs).
• Failure to integrate with QMS: The sampling plan operates in isolation, not fully integrated into the broader quality management system.
• Reliance solely on CE Mark: Assuming the CE mark alone guarantees conformity without conducting any further checks. For more context, see Why the CE mark alone is not evidence of conformity.
• Neglecting national requirements: Not verifying specific national requirements that might apply to device labelling or instructions for use, which vary by Member State. Consult your national competent authority for these specifics.

#Documentation and Review

All aspects of the sampling plan, including the methodology, results, and any corrective actions taken, must be thoroughly documented. This documentation forms part of the quality management system records and is subject to audit. The plan should be reviewed regularly, at least annually, and updated as necessary, for example, following significant changes to products, suppliers, or regulatory requirements.

#EUDAMED and Market Surveillance

The EUDAMED database plays a central role in post-market surveillance. While direct sampling results are not uploaded, the data collected through sampling informs the importer and distributor's vigilance activities and their ability to cooperate with competent authorities. Non-conformities or incidents discovered through sampling may need to be reported to manufacturers and national competent authorities, aligning with Article 14(4) and 13(5) MDR, or Article 12(4) and 11(5) IVDR. The current status and scope of EUDAMED modules should be confirmed with your national competent authority, as not all modules are fully mandatory or functional in all Member States at present.

EUDAMED facilitates the exchange of information, making it easier to identify trends and potential issues across the EU. Leveraging tools like the EUDAMED AI platform can streamline the management of regulatory information and obligations, helping you to stay abreast of market surveillance requirements and to manage your data efficiently. Learn more about how this works at https://eudamedai.com/#kako-deluje.

This material is for information only and is not legal advice. For binding interpretation consult your national competent authority.